Long-term data with idebenone on respiratory function outcomes in patients with Duchenne muscular dystrophy
Decline in respiratory function in patients with DMD starts during early teenage years and leads to early morbidity and mortality. Published evidence of efficacy for idebenone on respiratory function outcomes is currently limited to 12 months of follow-up time. Here we report data collected as retro...
Autori principali: | Servais, L, Straathof, CSM, Schara, U, Klein, A, Leinonen, M, Hasham, S, Meier, T, De Waele, L, Gordish-Dressman, H, McDonald, CM, Mayer, OH, Voit, T, Mercuri, E, Buyse, GM |
---|---|
Natura: | Journal article |
Lingua: | English |
Pubblicazione: |
Elsevier
2019
|
Documenti analoghi
Documenti analoghi
-
Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy
di: Theodora Markati, et al.
Pubblicazione: (2021-11-01) -
Evidence for ACTN3 as a genetic modifier of Duchenne muscular dystrophy
di: Marshall W. Hogarth, et al.
Pubblicazione: (2017-01-01) -
Cholesterol metabolism is a potential therapeutic target in Duchenne muscular dystrophy
di: Fatima Amor, et al.
Pubblicazione: (2021-06-01) -
Genetic modifiers of respiratory function in Duchenne muscular dystrophy
di: Luca Bello, et al.
Pubblicazione: (2020-05-01) -
Duchenne Muscular Dystrophy
di: J Gordon Millichap
Pubblicazione: (1989-05-01)